omniture

西安天美生物科技宣布2021財(cái)年財(cái)報(bào)創(chuàng)下新高

- 收入增加39.9%,達(dá)到2549萬美元
- 2021財(cái)年全年實(shí)現(xiàn)凈收入460萬美元,稀釋后每股收益達(dá)到0.68美元

西安2022年2月3日 /美通社/ -- 西安天美生物科技股份有限公司(納斯達(dá)克代碼:BON)(“天美生物”或“公司”),一家在天然、健康和個(gè)人護(hù)理行業(yè)提供關(guān)鍵活性成分及解決方案的領(lǐng)先供應(yīng)商,今天宣布其截至2021年9月30日的全年財(cái)務(wù)業(yè)績。

2021財(cái)年財(cái)務(wù)亮點(diǎn)

  • 總收入為2549萬美元,比2020年同期的1820萬美元增長了39.9%。
  • 毛利潤從2020年同期的520萬美元增加到710萬美元,增長了36.7%。
  • 管理費(fèi)用從2020年同期的140萬美金降至130萬美金,同比下降3.2%,或43,344美元。
  • 政府補(bǔ)助列示為其它運(yùn)營收入,2021和2020財(cái)年分別為449,972和362,187美元。
  • 凈利潤從2020年同期的310萬美元增加到461萬美元,增長了48.8%。
  • 調(diào)整后的息稅折舊攤銷前利潤2021年財(cái)年較2020年同比增長了46.5%,由421萬美金增至612萬美金。
  • 稀釋后每股收益(“EPS”)為0.68美元,2020年同期為0.58美元。
  • 與2020年同期相比,2021年財(cái)年香料原料和膳食補(bǔ)充劑(固體飲料)大類產(chǎn)品銷量增長7.9%和51.7%。生物活性食品原料產(chǎn)品銷量2021年財(cái)年同比略微下降5.7%。

*本新聞稿末尾的附表包含財(cái)報(bào)的GAAP和非GAAP指標(biāo)的調(diào)整。關(guān)于我們非GAAP指標(biāo)的調(diào)整,請參見非GAAP財(cái)務(wù)指標(biāo)的解釋。                                                                                          

管理層討論

“我們對公司業(yè)務(wù)的強(qiáng)勁需求的趨勢感到高興,并且對公司實(shí)現(xiàn)了兩位數(shù)的銷售增長和創(chuàng)下新高的收入感到自豪。這些結(jié)果充分的說明了我們強(qiáng)大的產(chǎn)品力、持續(xù)創(chuàng)新能力、以及我們作為客戶重要合作伙伴的價(jià)值?!?天美生物公司董事長兼CEO胡永衛(wèi)先生表示,“在短期內(nèi),因?yàn)槿蛞咔榈木猛喜粵Q、全球貿(mào)易關(guān)系和宏觀經(jīng)融政策的變化,我們面臨著前所未有的全球供應(yīng)鏈挑戰(zhàn)以及通貨膨脹相關(guān)的原材料和物流相關(guān)成本的增加,但我相信我們團(tuán)隊(duì)完全有能力應(yīng)對這些困境和壓力。并且我們將“轉(zhuǎn)為危機(jī)”,以此為契機(jī)推動(dòng)公司的產(chǎn)品組合轉(zhuǎn)向更技術(shù)含量和更高利潤的產(chǎn)品系列,以增加我們的定價(jià)能力,獲取更高的利潤率;同時(shí)我們將提升優(yōu)化產(chǎn)能,并實(shí)施強(qiáng)而有力的成本控制措施。值得一提的是,我們以人體微生物為靶標(biāo)的終端系列產(chǎn)品2021年取得了顯著進(jìn)展,隨著我們?nèi)烊粋€(gè)人護(hù)理產(chǎn)品-羽淳的成功推出,以及水蘇糖益生菌粉等其他一系列產(chǎn)品陸續(xù)上市,在強(qiáng)大產(chǎn)品力和巨大市場需求的驅(qū)動(dòng)下,我們對自己在終端用戶市場快速取得的進(jìn)展有充分的信心。最后一點(diǎn),隨著今年玉門工廠的完成投產(chǎn),將能帶來150%的收入增長,也使得我們能更高效地服務(wù)來自國內(nèi)外的客戶,加速我們的全球業(yè)務(wù)擴(kuò)張計(jì)劃,并為我們的投資者創(chuàng)造持久的長期價(jià)值。” 

2021財(cái)年產(chǎn)品(按類別)與上年相比增長總結(jié):


收入增加(減少)

毛利潤增加(減少)

香料原料

61.7%

82.3%

膳食補(bǔ)充劑(固體飲料)

71.2%

81.8%

生物活性食品原料

(5.6%)

(14.2%)

香料原料

  • 香料原料的銷售收入從2020年同期的790萬美元增加了61.7%,達(dá)到1270萬美元。這一增長主要是由于銷量和平均售價(jià)分別增加了7.9%和39.2%,以及匯率帶來的7.1%的增長。
  • 香料原料的毛利潤從2020年同期的160萬美元增加82.3%至295萬美元。增長的原因與上述相同。

膳食補(bǔ)充劑(固體飲料)

  • 膳食補(bǔ)充劑(固體飲料)產(chǎn)品的銷售收入從2020年同期的389萬美元增加到670萬美元,增長了71.2%。這一增長是由于銷售量和平均售價(jià)分別增長51.7%和4.9%,以及匯率帶來7.1%的增長。
  • 膳食補(bǔ)充劑(固體飲料)的毛利潤從2020年同期的113萬美元增加到210萬美元,增長了81.8%。增長的原因與上述相同。

生物活性食品原料

  • 生物活性食品原料的銷售收入從2020年同期的645萬美元減少5.6%至610萬美元。減少的主要原因是銷售量減少了5.7%以及平均售價(jià)減少了7.0%。在2021年,新冠疫情在中國的傳播得到控制,我們生物活性食品原料產(chǎn)品-水蘇糖的客戶訂單因此減少,同時(shí)并被匯率帶來的7.1%的增長所抵消。
  • 生物活性食品原料的毛利潤從2020年同期的245萬美元減少14.2%至210萬美元。減少的原因與上述相同。

銷售費(fèi)用從161,719美元減少到2021年同期的138,530美元,減少了23,189美元,或約14.3%。減少的原因是公司通過網(wǎng)絡(luò)營銷和銷售推廣,將重點(diǎn)轉(zhuǎn)向國內(nèi)大型客戶,從而實(shí)現(xiàn)成本節(jié)約。

研究和開發(fā)費(fèi)用從2020財(cái)年的205,359美元增長至249,050美元,增長了43,691美元,或約21.3%。增長的主要原因是研究材料的消耗增長了26,391美元以及研發(fā)測試和檢驗(yàn)相關(guān)的費(fèi)用增長了10,647美元。

政府補(bǔ)貼以補(bǔ)貼形式獲得并確認(rèn)為其他營業(yè)收入,在截至2021年9月30日和2020年9月30日的財(cái)年里,總額分別為446,910美元和332,418美元。

凈利潤從截止至2020年9月30日財(cái)年的310萬美元增長至2021年同期的461萬美元。

經(jīng)營活動(dòng)產(chǎn)生的凈現(xiàn)金在截止至2021年9月30日的財(cái)年期間為405萬美元,2020年同期為264萬美元。

每股基本收益(EPS為0.69美元,2020年同期為0.58美元。

稀釋后每股收益(EPS為0.68美元,2020年同期為0.58美元。

報(bào)告期后事件

  • 2021年11月11日,公司宣布其取消可變利益實(shí)體(“VIE”)架構(gòu),成為其在中國經(jīng)營實(shí)體的唯一股東。
  • 2022年1月12日,公司宣布收到了重慶福兜兜科技公司的首個(gè)以水蘇糖和蘋果提取物為基礎(chǔ)的個(gè)人護(hù)理產(chǎn)品-羽淳的第一批采購訂單,以打入消費(fèi)者市場。

投資者電話會(huì)議和網(wǎng)絡(luò)直播

討論公司2021年財(cái)年財(cái)務(wù)業(yè)績的網(wǎng)絡(luò)直播將于2022年2月3日美國東部時(shí)間上午9:00開始。網(wǎng)絡(luò)直播和相關(guān)PPT的獲取可以訪問公司的投資者網(wǎng)站 https://ir.bnlus.com/events-presentations/。對于無法觀看網(wǎng)絡(luò)直播的人,在活動(dòng)結(jié)束后公司將在網(wǎng)站上提供錄制版本。

西安天美生物有限公司

西安天美生物專注于膳食營養(yǎng)補(bǔ)充劑的生物活性成分的生產(chǎn),如為食品制造商提供天然益生元;個(gè)人護(hù)理成分的生產(chǎn),如為香水香料制造商提供從植物來源的香料原料,天然復(fù)配膳食補(bǔ)充劑生產(chǎn),如固體飲料。欲了解更多信息,請?jiān)L問公司網(wǎng)站:www.bnlus.com.

安全港聲明

本新聞稿包含了1995年《私人證券訴訟改革法案》中的前瞻性聲明。前瞻性聲明包括了有關(guān)公司計(jì)劃、目標(biāo)、戰(zhàn)略、未來事件或業(yè)績的聲明,以及其他假設(shè)和不包含歷史事件的聲明。當(dāng)公司使用諸如“可能”、“將”、“打算”、“應(yīng)該”、“相信”、“期望”、“預(yù)期”、“計(jì)劃”、“估計(jì)”等或其他類似的表達(dá)方式,并不與歷史事件有關(guān),就是在做前瞻性聲明。前瞻性聲明不是對公司未來業(yè)績的保證,涉及風(fēng)險(xiǎn)和不確定性,可能會(huì)導(dǎo)致實(shí)際結(jié)果與前瞻性聲明中討論的公司預(yù)期有實(shí)質(zhì)性的差異。這些陳述受不確定性和風(fēng)險(xiǎn)因素的印象,包括但不限于:公司的目標(biāo)和戰(zhàn)略、公司的未來業(yè)務(wù)發(fā)展、公司產(chǎn)品和服務(wù)的需求、技術(shù)的變化、經(jīng)濟(jì)狀況、中國天然健康和個(gè)人護(hù)理行業(yè)的發(fā)展及公司希望發(fā)展的其他國際市場、聲譽(yù)和品牌、競爭和定價(jià)的影響、政府法規(guī)、中國及公司希望發(fā)展的其他國際市場的經(jīng)濟(jì)和商業(yè)狀況的變動(dòng),以及與上述任何情況相關(guān)的假設(shè)和公司提交給SEC報(bào)告中所陳述的其他風(fēng)險(xiǎn)。因此,我們提醒投資者不要過分依賴本新聞稿中的前瞻性陳述。公司向SEC提交的文件中討論了其他因素,這些文件可在www.sec.gov上查閱。公司不承擔(dān)公開修訂本聲明日期之后出現(xiàn)的事件或情況的前瞻性聲明的義務(wù)。

更多信息,請聯(lián)系:

In the United States:

In China:

Maggie Zhang | Impact IR

Sophie Zhang | Impact IR

Phone: (646) 893-8916

Email: sophie.zhang@irimpact.com

Email: maggie.zhang@irimpact.com 


BON NATURAL LIFE LIMITED AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS










September 30




2021



2020


ASSETS









CURRENT ASSETS









Cash


$

1,903,867



$

53,106


Short-term investments



1,703,314




-


Accounts receivable, net



6,152,807




5,771,008


Inventories, net



1,596,492




1,016,442


Advance to suppliers, net



4,094,312




3,491,145


Deferred initial public offering costs



-




510,079


Acquisition deposit



1,000,000




-


Prepaid expenses and other current assets



98,960




7,434


TOTAL CURRENT ASSETS



16,549,752




10,840,214











Property, plant and equipment, net



19,228,642




14,171,963


Intangible assets, net



411,056




140,993


Right-of-use lease assets, net



201,007




-


Deferred tax assets, net



22,342




49,059


TOTAL ASSETS


$

36,412,799



$

25,202,229











LIABILITIES AND EQUITY









CURRENT LIABILITIES









Short-term loans


$

41,381



$

1,289,081


Current portion of long-term loans



448,005




1,227,346


Third party loans



-




690,327


Accounts payable



380,385




1,288,629


Due to related parties



245,104




2,322,990


Taxes payable



5,052,018




4,402,625


Deferred revenue



1,096,101




385,978


Accrued expenses and other current liabilities



41,711




56,604


Finance lease liabilities, current



161,286




33,389


Operating lease liability, current



62,871




-


TOTAL CURRENT LIABILITIES


$

7,528,862



$

11,696,969


Long-term loans



2,173,532




2,482,251


Finance lease liabilities, noncurrent



28,953




-


Operating lease liability, noncurrent



146,703




-


TOTAL LIABILITIES



9,878,050




14,179,220











COMMITMENTS AND CONTINGENCIES



-




-


EQUITY









Ordinary shares, $0.0001 par value, 500,000,000 shares authorized, 8,330,000 and 5,800,000 shares issued and outstanding as of September 30, 2021 and 2020, respectively


$

833



$

580


Additional paid in capital



15,540,433




5,251,205


Statutory reserve



1,050,721




579,922


Retained earnings



9,192,676




5,072,672


Accumulated other comprehensive income (loss)



222,221




(388,102)


TOTAL BON NATURAL LIFE LIMITED SHAREHOLDERS’ EQUITY



26,006,884




10,516,277


Non-controlling interest



527,865




506,732


Total equity



26,534,749




11,023,009


TOTAL LIABILITIES AND EQUITY


$

36,412,799



$

25,202,229


 

BON NATURAL LIFE LIMITED AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME













For the Years Ended September 30,




2021



2020



2019


REVENUE


$

25,494,564



$

18,219,959



$

16,396,018


COST OF REVENUE



(18,382,637)




(13,017,646)




(11,113,922)


GROSS PROFIT



7,111,927




5,202,313




5,282,096















OPERATING EXPENSES













Selling expenses



(138,530)




(161,719)




(273,841)


General and administrative expenses



(1,323,726)




(1,367,070)




(1,310,215)















Research and development expenses



(249,050)




(205,359)




(522,867)


Total operating expenses



(1,711,306)




(1,734,148)




(2,106,923)















INCOME FROM OPERATIONS



5,400,621




3,468,165




3,175,173















OTHER INCOME (EXPENSES)













Interest income



3,207




714




2,271


Interest expense



(417,266)




(329,102)




(333,190)


Unrealized foreign transaction exchange gain (loss)



(45,124)




(248)




5,281


Gain on disposal of fixed assets



-




20,150




-


Government subsidies



449,972




362,187




140,295


Income from short-term investments



565




-




-


Other income



38,409




132,713




-


Total other income (expenses), net



29,763




186,414




(185,343)















INCOME BEFORE INCOME TAX PROVISION



5,430,384




3,654,579




2,989,830















INCOME TAX PROVISION



(820,931)




(556,262)




(427,194)















NET INCOME



4,609,453




3,098,317




2,562,636


Less: net income (loss) attributable to non-controlling interest



18,650




71,644




(11,167)


NET INCOME ATTRIBUTABLE TO BON NATURAL LIFE LIMITED


$

4,590,803



$

3,026,673



$

2,573,803















OTHER COMPREHENSIVE INCOME (LOSS)













Total foreign currency translation adjustment



612,806




450,234




(281,699)


TOTAL COMPREHENSIVE INCOME



5,222,259




3,548,551




2,280,937


Less: comprehensive income (loss) attributable to non-controlling interest



21,133




81,737




(10,969)


COMPREHENSIVE INCOME ATTRIBUTABLE TO BON NATURAL LIFE LIMITED


$

5,201,126



$

3,466,814



$

2,291,906















EARNINGS PER SHARE













Basic


$

0.69



$

0.58



$

0.50


Diluted


$

0.68



$

0.58



$

0.50















WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING













Basic



6,615,833




5,210,649




5,166,667


Diluted



6,706,235




5,210,649




5,166,667


 

BON NATURAL LIFE LIMITED AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS













For the Years Ended September 30,




2021



2020



2019


Cash flows from operating activities













Net income


$

4,609,453



$

3,098,317



$

2,562,636


Adjustments to reconcile net income to cash provided by operating activities













Allowance for doubtful accounts



2,948




22,137




34,328


Depreciation and amortization



228,547




230,597




226,633


Inventory reserve (recovery)



(312,532)




29,539




-


Deferred income tax



29,109




(7,751)




(5,149)


Amortization of operating lease right-of-use assets



58,147




-






Amortization of stock options



44,910




-




-


Unrealized foreign currency exchange loss (gain)



45,124




248




(5,281)


Gain on disposal of property and equipment



-




(20,150)




-


Changes in operating assets and liabilities:













Accounts receivable



(89,543)




(284,546)




(2,912,222)


Inventories



(209,011)




1,636,321




6,681,972


Advance to suppliers, net



(399,262)




(3,021,739)




168,868


Prepaid expenses and other current assets



2,642




72,116




173,609


Accounts payable



(969,414)




(1,982,205)




(78,356)


Operating lease liabilities



(49,648)




-




-


Taxes payable



410,716




2,662,542




1,538,662


Deferred revenue



684,030




161,045




(1,223,824)


Accrued expenses and other current liabilities



(33,092)




46,605




(57,053)


Net cash provided by operating activities



4,053,124




2,643,076




7,104,823















Cash flows from investing activities













Purchase of short-term investments



(2,159,920)




-




-


Proceeds upon redemption of short-term investments



470,082




-




-


Purchase of property and equipment



(51,878)




(31,885)




(213,634)


Capital expenditures on construction-in-progress



(4,432,941)




(4,301,103)




(6,861,257)


Purchase of intangible assets



(269,088)




-




-


Refund (payment) of acquisition deposit



(1,000,000)




1,329,945




(1,355,067)


Net cash used in investing activities



(7,443,745)




(3,003,043)




(8,429,958)















Cash flows from financing activities













Net proceeds from issuance of Ordinary Shares in initial public offerings



11,271,480




-




-


Proceeds from short-term loans



1,257,225




2,033,570




4,008,293


Proceeds from long-term loans



1,245,871




319,342




-


Repayment of short-term loans



(2,563,433)




(2,872,778)




(4,514,482)


Repayment of long-term loans



(2,522,101)




-




-


Proceeds from (repayment of) borrowings from related parties



(2,262,378)




1,067,808




543,976


Proceeds from (repayment of) third party loans



(721,484)




238,133




(101,793)


Principal payment from (repayment of) finance lease



169,153




(392,030)




432,722


Capital contribution from non-controlling interest



-




-




435,964


Payment for deferred initial public offering costs



(521,651)




(281,553)




-


Net cash provided by financing activities



5,352,682




112,492




804,680















Effect of changes of foreign exchange rates on cash



(111,300)




6,810




(6,630)


Net increase (decrease) in cash



1,850,761




(240,665)




(527,085)


Cash, beginning of year



53,106




293,771




820,856


Cash, end of year


$

1,903,867



$

53,106



$

293,771















Supplemental disclosure of cash flow information













Cash paid for interest expense


$

417,266



$

276,671



$

333,190


Cash paid for income tax


$

2,411



$

-



$

115,179


Supplemental disclosure of non-cash investing and financing activities













Amortization of share-based compensation for initial public offering services


$

422,221



$

211,112



$

-


Right-of-use assets obtained in exchange for operating lease obligations


$

257,564



$

-



$

-


 

Bon Natural Life Limited
GAAP to Non-GAAP Reconciliation

The following information and schedules provide reconciliation information between reported GAAP amounts and non-GAAP certain adjusted amounts. This information and schedules are not intended as, and should not be viewed as, a substitute for reported GAAP amounts or financial statements of the Company prepared and presented in accordance with GAAP.

Reconciliation of Adjusted EBITDA to Net Income


 30-Sep


2021


2020

 Net income

$

4,609,453


$

3,098,317

 Interest expense


417,266



329,102

 Income taxes


820,931



556,262

 Depreciation and amortization


228,547



230,597

 Non-cash item(1)


44,910



-

 Adjusted EBITDA

$

6,121,107


$

4,214,278

(1) Non-cash item represents adjustment of stock-based compensation to reconcile net income to net cash provided by operations as presented on the Statement of Cash Flows 

消息來源:西安天美生物科技股份有限公司
相關(guān)股票:
NASDAQ:BON
China-PRNewsire-300-300.png
醫(yī)藥健聞
微信公眾號(hào)“醫(yī)藥健聞”發(fā)布全球制藥、醫(yī)療、大健康企業(yè)最新的經(jīng)營動(dòng)態(tài)。掃描二維碼,立即訂閱!
collection